Brief: Eagle Pharmaceuticals reports Q2 results

Eagle Pharmaceuticals

09/08/2022 11:54

Aug 9 (Reuters) - Eagle Pharmaceuticals Inc  EGRX.O :
    * EAGLE PHARMACEUTICALS REPORTS SECOND QUARTER 2022 RESULTS
    * CASH AND NET RECEIVABLES TOTALED $122.5 MILLION AT JUNE
30,
2022, AFTER ACQUISITION OF ACACIA PHARMA GROUP PLC
    * EAGLE PHARMACEUTICALS - Q2 NET LOSS $0.74 PER BASIC AND
DILUTED
SHARE, ADJUSTED NON-GAAP NET INCOME $1.58 PER BASIC AND $1.56
PER DILUTED SHARE
    * EAGLE PHARMACEUTICALS - CASH AND CASH EQUIVALENTS WERE
$36.6
MILLION, NET ACCOUNTS RECEIVABLE WAS $85.9 MILLION, AND DEBT WAS
$50.0 MILLION, AS OF JUNE 30, 2022
    * EAGLE PHARMACEUTICALS - ADJUSTED NON-GAAP RESEARCH AND
DEVELOPMENT EXPENSE FOR FULL YEAR 2022 IS EXPECTED TO BE IN
RANGE OF $46 MILLION TO $50 MILLION
    * Q2 EARNINGS PER SHARE VIEW $3.36 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX6Hh0wK 
Further company coverage:  EGRX.O